Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Juhaeri Juhaeri

Showing results (1-10 of 48) with videos related to

Pageof 5
Sort By:
Therapeutic Advances in Drug Safety|September 7, 2019
Benefit-risk evaluation: the past, present and futureJuhaeri Juhaeri
Clinical Therapeutics|December 5, 2016
The US Food and Drug Administration's Risk Evaluation and Mitigation Strategy (REMS) Program - Current Status and Future DirectionJasmanda Wu, Juhaeri Juhaeri
Obesity (Silver Spring, Md.)|February 3, 2009
The incidence rate of seizures in relation to BMI in UK adultsShujun Gao, Juhaeri Juhaeri, Wanju S Dai
Pharmacoepidemiology and Drug Safety|October 16, 2003
Benefit-risk analysis: a proposal using quantitative methodsWilliam L Holden, Juhaeri Juhaeri, Wanju Dai
Pharmacoepidemiology and Drug Safety|March 28, 2009
Incidence rates of heart failure, stroke, and acute myocardial infarction among Type 2 diabetic patients using insulin glargine and other insulinJuhaeri Juhaeri, Shujun Gao, Wanju S Dai
Diabetes Care|February 2, 2018
Trends in Hospital Admission for Diabetic Ketoacidosis in Adults With Type 1 and Type 2 Diabetes in England, 1998-2013: A Retrospective Cohort StudyVictor W Zhong, Juhaeri Juhaeri, Elizabeth J Mayer-Davis
The Journal of Allergy and Clinical Immunology|April 6, 2016
Intranasal triamcinolone use during pregnancy and the risk of adverse pregnancy outcomesAnick Bérard, Odile Sheehy, Marie-Laure Kurzinger, et al.
Cancer Epidemiology|March 5, 2015
Risk of Wernicke's encephalopathy and cardiac disorders in patients with myeloproliferative neoplasmJasmanda Wu, Ling Zhang, Anjali Vaze, et al.
Pharmacoepidemiology and Drug Safety|March 12, 2025
Real-World Data and Real-World Evidence in Regulatory Decision Making: Report Summary From the Council for International Organizations of Medical Sciences (CIOMS) Working Group XIIISean Hennessy, Yoshiko Atsuta, Sanna Hill, et al.
Frontiers in Drug Safety and Regulation|June 26, 2026
Methodological comparisons for benefit-risk assessment in complex decision-making: applications and insights from a case studyJian-Yu E, Kexin Zhu, Stéphanie Tcherny-Lessenot, et al.
Pageof 5

Showing results (1-10 of 48) with videos related to

Sort By:
Pageof 5
Therapeutic Advances in Drug Safety|September 7, 2019
Benefit-risk evaluation: the past, present and futureJuhaeri Juhaeri
Clinical Therapeutics|December 5, 2016
The US Food and Drug Administration's Risk Evaluation and Mitigation Strategy (REMS) Program - Current Status and Future DirectionJasmanda Wu, Juhaeri Juhaeri
Obesity (Silver Spring, Md.)|February 3, 2009
The incidence rate of seizures in relation to BMI in UK adultsShujun Gao, Juhaeri Juhaeri, Wanju S Dai
Pharmacoepidemiology and Drug Safety|October 16, 2003
Benefit-risk analysis: a proposal using quantitative methodsWilliam L Holden, Juhaeri Juhaeri, Wanju Dai
Pharmacoepidemiology and Drug Safety|March 28, 2009
Incidence rates of heart failure, stroke, and acute myocardial infarction among Type 2 diabetic patients using insulin glargine and other insulinJuhaeri Juhaeri, Shujun Gao, Wanju S Dai
Diabetes Care|February 2, 2018
Trends in Hospital Admission for Diabetic Ketoacidosis in Adults With Type 1 and Type 2 Diabetes in England, 1998-2013: A Retrospective Cohort StudyVictor W Zhong, Juhaeri Juhaeri, Elizabeth J Mayer-Davis
The Journal of Allergy and Clinical Immunology|April 6, 2016
Intranasal triamcinolone use during pregnancy and the risk of adverse pregnancy outcomesAnick Bérard, Odile Sheehy, Marie-Laure Kurzinger, et al.
Cancer Epidemiology|March 5, 2015
Risk of Wernicke's encephalopathy and cardiac disorders in patients with myeloproliferative neoplasmJasmanda Wu, Ling Zhang, Anjali Vaze, et al.
Pharmacoepidemiology and Drug Safety|March 12, 2025
Real-World Data and Real-World Evidence in Regulatory Decision Making: Report Summary From the Council for International Organizations of Medical Sciences (CIOMS) Working Group XIIISean Hennessy, Yoshiko Atsuta, Sanna Hill, et al.
Frontiers in Drug Safety and Regulation|June 26, 2026
Methodological comparisons for benefit-risk assessment in complex decision-making: applications and insights from a case studyJian-Yu E, Kexin Zhu, Stéphanie Tcherny-Lessenot, et al.
Pageof 5